Business Description
Qiagen NV
NAICS : 541720
SIC : 8733
ISIN : NL0015002SN0
Share Class Description:
XTER:QIA: Ordinary SharesTotal Employee Number:
5,500Compare
Compare
Traded in other countries / regions
QGEN.USAQIA.Germany0RLT.UKQGE4.Austria1QGEN.Italy Index Membership
STOXX Europe 600DAX 30MSCI World Index IPO Date
1997-09-25Description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | 2.37 | |||||
Interest Coverage | 13.83 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.63 | |||||
Beneish M-Score | -2.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.1 | |||||
3-Year EBITDA Growth Rate | -2 | |||||
3-Year EPS without NRI Growth Rate | -5.1 | |||||
3-Year FCF Growth Rate | -6.9 | |||||
3-Year Book Growth Rate | 2.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.26 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.38 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.06 | |||||
9-Day RSI | 48.19 | |||||
14-Day RSI | 53.39 | |||||
3-1 Month Momentum % | 16.76 | |||||
6-1 Month Momentum % | -24.03 | |||||
12-1 Month Momentum % | -26.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.21 | |||||
Quick Ratio | 2.57 | |||||
Cash Ratio | 1.35 | |||||
Days Inventory | 134.91 | |||||
Days Sales Outstanding | 66.13 | |||||
Days Payable | 34.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.86 | |||||
Dividend Payout Ratio | 0.11 | |||||
Forward Dividend Yield % | 0.86 | |||||
5-Year Yield-on-Cost % | 0.85 | |||||
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -1.47 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.96 | |||||
Operating Margin % | 24.38 | |||||
Net Margin % | 19.16 | |||||
EBITDA Margin % | 33.09 | |||||
FCF Margin % | 19.23 | |||||
OCF Margin % | 29.29 | |||||
ROE % | 11.38 | |||||
ROA % | 6.71 | |||||
ROIC % | 9.91 | |||||
3-Year ROIIC % | -8.15 | |||||
ROC (Joel Greenblatt) % | 39.42 | |||||
ROCE % | 9.36 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 21.33 | |||||
Forward PE Ratio | 17.11 | |||||
PE Ratio without NRI | 17.58 | |||||
Shiller PE Ratio | 30.28 | |||||
Price-to-Owner-Earnings | 24.14 | |||||
PS Ratio | 4.1 | |||||
PB Ratio | 2.56 | |||||
Price-to-Tangible-Book | 31.89 | |||||
Price-to-Free-Cash-Flow | 21.29 | |||||
Price-to-Operating-Cash-Flow | 13.98 | |||||
EV-to-EBIT | 19.33 | |||||
EV-to-Forward-EBIT | 15.46 | |||||
EV-to-EBITDA | 13.73 | |||||
EV-to-Forward-EBITDA | 11.75 | |||||
EV-to-Revenue | 4.54 | |||||
EV-to-Forward-Revenue | 4.28 | |||||
EV-to-FCF | 23.62 | |||||
Price-to-GF-Value | 0.79 | |||||
Price-to-Projected-FCF | 1.35 | |||||
Price-to-Median-PS-Value | 0.76 | |||||
Price-to-Graham-Number | 4.99 | |||||
Earnings Yield (Greenblatt) % | 5.17 | |||||
FCF Yield % | 4.73 | |||||
Forward Rate of Return (Yacktman) % | -7.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qiagen NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,803.716 | ||
| EPS (TTM) (€) | 1.665 | ||
| Beta | 1.0318 | ||
| 3-Year Sharpe Ratio | -0.4 | ||
| 3-Year Sortino Ratio | -0.49 | ||
| Volatility % | 36.01 | ||
| 14-Day RSI | 53.39 | ||
| 14-Day ATR (€) | 1.035126 | ||
| 20-Day SMA (€) | 35.85475 | ||
| 12-1 Month Momentum % | -26.47 | ||
| 52-Week Range (€) | 27.56 - 47.595 | ||
| Shares Outstanding (Mil) | 206.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qiagen NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qiagen NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Citi Global Healthcare Conference | 2026-12-02 09:00 | In 123 days | ||
| Guidance call for 2026 | 2026-12-01 09:00 | In 122 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 09:30 | In 96 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 16:05 | In 95 days | ||
| Guidance call for 2026 | 2026-09-22 08:00 | In 52 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 09:30 | In 5 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 16:05 | In 4 days | ||
| USD 0.350000 Cash Dividend | 2026-07-07 | 34.08 (-2.34%) | ||
| General meeting for 2026 | 2026-06-24 09:00 | 32.61 (+1.16%) | ||
| Guidance call for 2025 | 2026-06-03 11:40 | 30.71 (-0.68%) |
Show
Entries
Qiagen NV Frequently Asked Questions
What is Qiagen NV(XTER:QIA)'s stock price today?
The current price of XTER:QIA is €35.72. The 52 week high of XTER:QIA is €47.60 and 52 week low is €27.56.
When is next earnings date of Qiagen NV(XTER:QIA)?
The next earnings date of Qiagen NV(XTER:QIA) is 2026-08-05.
Does Qiagen NV(XTER:QIA) pay dividends? If so, how much?
The Dividend Yield %  of Qiagen NV(XTER:QIA) is 0.86% (As of Today), Highest Dividend Payout Ratio of Qiagen NV(XTER:QIA) was 0.12. The lowest was 0.11. And the median was 0.12. The  Forward Dividend Yield % of Qiagen NV(XTER:QIA) is 0.86%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Qiagen NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers